Urovant Sciences

Improving quality of life through innovations in urology.

Vibegron

Our lead product candidate, vibegron, is an investigational oral, once-daily, small molecule beta-3 agonist, being developed for overactive bladder (OAB), OAB in men with benign prostatic hyperplasia (BPH) and pain associated with irritable bowel syndrome (IBS).

LEARN MORE

Latest News

The latest posts and articles

Urovant Sciences to Report First Fiscal...
on August 6, 2020
IRVINE, Calif. & BASEL, Switzerland --(BUSINESS WIRE)--Aug. 6, 2020-- Urovant Sciences (Nasdaq: […]
Read Latest Post
Urovant Sciences Reports Fiscal Year and...
on June 18, 2020
IRVINE, Calif. & BASEL, Switzerland --(BUSINESS WIRE)--Jun. 18, 2020-- Urovant Sciences […]
Read Latest Post
Urovant Sciences Announces Collaboration...
on June 18, 2020
IRVINE, Calif. & BASEL, Switzerland --(BUSINESS WIRE)--Jun. 18, 2020-- Urovant Sciences […]
Read Latest Post

View more

info@urovant.com | Healthcare Professionals Sign Up